The Arche CLUE Program generates a significant ROI for your health plan.
Program costs are comprised of both reoccurring annual costs and a one-time fee for the highest risk members to receive a home-monitoring device for early detection of ulceration risk.
The reoccurring costs are for members to receive the level of care that they should as determined by evidence-based guidelines and protocols. Each person with diabetes should have an annual Comprehensive Diabetic Foot Examination (CDFE), and those that are eligible should receive a prescription for therapeutic footwear and insoles. The incremental increase in annual cost in this model reflects the change in adherence to the evidence-based protocol that supports these interventions in your population of people with diabetes, thus reducing the incidence of Diabetic Foot Ulcers and Lower Extremity Amputations, resulting in lower morbidity, mortality and cost.
The highest risk members with diabetes in your population, stratified in Risk Levels 2 and 3 based on their CDFE will be given an Arche Healthcare Verisole Home Monitoring System. This results in the onetime cost noted in the cost and ROI calculations.
We have presented the ROI in two ways. The first reflects the one-time cost of the Verisole Home Monitoring Kit fully realized in Year 1. The second amortizes the cost of the Verisole Home Monitoring Kit over two years.